Sally E Boero, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 2 carriers
- Office
- 1
- Since medical school
- 30 years
- University of California, Geffen School of Medicine, 1996
Offices
1 location · Regents Univ of California UCSF · 276 clinicians in this group
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plans that list them
11 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boero’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A64736 · Current
Licensed to practise in California · since 1998 · expires 2028-04-30 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$14,791
Medicare paid this office $14,791 for 121 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 56 | $4,491 | $72 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 57 | $2,569 | $45 |
| Return visit (30+ min) | 22 | $2,439 | $106 |
| Long return visit (40+ min) | 13 | $2,427 | $162 |
| Short return visit | 19 | $974 | $46 |
Who their Medicare patients are
121 Original Medicare patients in 2024. Average age 73 · Women 100% · Health risk score 0.74. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 36% · Depression 17% · Cancer 15% · Coronary heart disease 10%.
The office billed $77,900, Medicare allowed $19,494 and paid $14,791; for 208 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 121 | 208 | 73 | 0.74 | $77,900 | $14,791 |
| 2023 | 118 | 209 | 73 | 0.79 | $96,045 | $14,621 |
| 2022 | 142 | 259 | 73 | 0.71 | $107,162 | $18,879 |
| 2021 | 81 | 146 | 74 | 0.76 | $54,844 | $8,823 |
| 2020 | 104 | 164 | 71 | 0.64 | $79,266 | $8,377 |
| 2019 | 120 | 215 | 71 | 0.71 | $95,458 | $11,455 |
| 2018 | 121 | 207 | 71 | 0.65 | $26,682 | $9,600 |
| 2017 | 104 | 226 | 72 | 0.83 | $21,296 | $9,480 |
| 2016 | 115 | 249 | 71 | 0.72 | $26,025 | $11,620 |
| 2015 | 142 | 275 | 72 | 0.70 | $29,178 | $12,120 |
| 2014 | 109 | 233 | 68 | 0.76 | $37,517 | $14,337 |
| 2013 | 125 | 285 | 68 | 0.78 | $30,579 | $13,746 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 61 | $4,849 | $67 |
| Return visit (30+ min) | 25 | $2,530 | $94 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 53 | $2,382 | $45 |
| Short return visit | 16 | $991 | $52 |
2022: 4 services
| Short return visit (20+ min) | 67 | $6,636 | $81 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 77 | $3,404 | $44 |
| Return visit (30+ min) | 24 | $3,281 | $122 |
| Short return visit | 27 | $1,586 | $51 |
2021: 3 services
| Short return visit (20+ min) | 43 | $3,506 | $75 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 45 | $2,030 | $45 |
| Short return visit | 23 | $1,096 | $41 |
2020: 3 services
| Short return visit (20+ min) | 39 | $2,637 | $59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,293 | $45 |
| Short return visit | 25 | $879 | $29 |
2019: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 64 | $2,775 | $43 |
| Short return visit (20+ min) | 33 | $2,220 | $58 |
| Short return visit | 28 | $1,387 | $37 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $553 | $50 |
2018: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 60 | $2,630 | $44 |
| Short return visit (20+ min) | 30 | $2,004 | $59 |
| Short return visit | 35 | $1,863 | $37 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 27 | $1,427 | $53 |
| Urinalysis, manual test | 11 | $44 | $3 |
2017: 7 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 61 | $2,682 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $1,481 | $53 |
| Short return visit (20+ min) | 16 | $1,326 | $63 |
| Short return visit | 18 | $1,086 | $36 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 36 | $770 | $21 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $210 | $16 |
| Urinalysis, manual test | 14 | $48 | $3 |
2016: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 55 | $2,407 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 39 | $2,077 | $53 |
| Short return visit (20+ min) | 21 | $1,278 | $53 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 53 | $1,126 | $21 |
| Short return visit | 22 | $1,090 | $36 |
2015: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 78 | $3,417 | $44 |
| Short return visit (20+ min) | 38 | $2,756 | $59 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 68 | $1,443 | $21 |
| Short return visit | 19 | $834 | $36 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $640 | $53 |
2014: 5 services
| Short return visit (20+ min) | 26 | $2,671 | $61 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 35 | $1,504 | $43 |
| Return visit (30+ min) | 14 | $1,343 | $90 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $1,144 | $52 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 45 | $957 | $21 |
2013: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 59 | $2,541 | $43 |
| Short return visit (20+ min) | 32 | $2,383 | $57 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 37 | $1,969 | $53 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 55 | $1,183 | $22 |
| Return visit (30+ min) | 11 | $896 | $81 |
Drugs they prescribed that Part D paid
$41,189
Pharmacies billed $41,189 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 391) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
352 generic and 39 brand-name prescriptions · $41,189 in drug cost · 26 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 107 | $13,344 | $125 |
| Yuvafem | 24 | $3,738 | $156 |
| Estradiol (Twice Weekly) | 35 | $3,696 | $106 |
| Dotti | 26 | $3,332 | $128 |
| Valacyclovir | 33 | $2,782 | $84 |
See all 9 drugs
| Estradiol | 107 | $13,344 | $125 |
| Yuvafem | 24 | $3,738 | $156 |
| Estradiol (Twice Weekly) | 35 | $3,696 | $106 |
| Dotti | 26 | $3,332 | $128 |
| Valacyclovir | 33 | $2,782 | $84 |
| Progesterone | 48 | $1,371 | $29 |
| Clobetasol Propionate | 12 | $645 | $54 |
| Nitrofurantoin Mono-Macro | 12 | $193 | $16 |
| Fluconazole | 11 | $76 | $7 |
Year by year
| 2024 | 391 | 146 | 0% (0) | 10% | $41,189 |
| 2023 | 344 | 124 | None | 22% | $43,677 |
| 2022 | 363 | 113 | None | 22% | $45,458 |
| 2021 | 312 | 95 | 0% (0) | None | $36,870 |
| 2020 | 354 | 95 | 0% (0) | 15% | $43,078 |
| 2019 | 359 | 87 | None | 20% | $40,990 |
| 2018 | 281 | 76 | None | 17% | $34,891 |
| 2017 | 238 | 59 | None | 29% | $31,429 |
| 2016 | 200 | 56 | None | 36% | $22,212 |
| 2015 | 189 | 48 | None | 39% | $22,813 |
| 2014 | 175 | 44 | 0% (0) | None | $19,658 |
| 2013 | 112 | 32 | None | 39% | $8,914 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Estring | 19 | $10,234 | $539 |
| Estradiol | 68 | $7,867 | $116 |
| Estradiol (Twice Weekly) | 36 | $6,231 | $173 |
| Yuvafem | 15 | $3,359 | $224 |
| Valacyclovir | 26 | $2,132 | $82 |
| Dotti | 11 | $1,713 | $156 |
| Progesterone | 26 | $1,010 | $39 |
| Clobetasol Propionate | 11 | $499 | $45 |
| Fluconazole | 20 | $395 | $20 |
| Nitrofurantoin Mono-Macro | 12 | $298 | $25 |
| Acyclovir | 12 | $252 | $21 |
| Triamcinolone Acetonide | 13 | $54 | $4 |
2022: 9 drugs
| Estring | 18 | $9,041 | $502 |
| Estradiol | 85 | $8,964 | $105 |
| Estradiol (Twice Weekly) | 49 | $7,396 | $151 |
| Valacyclovir | 32 | $2,689 | $84 |
| Progesterone | 34 | $1,180 | $35 |
| Dotti | 15 | $1,030 | $69 |
| Clobetasol Propionate | 16 | $626 | $39 |
| Acyclovir | 14 | $587 | $42 |
| Fluconazole | 15 | $170 | $11 |
2021: 8 drugs
| Estradiol | 66 | $6,845 | $104 |
| Estradiol (Twice Weekly) | 34 | $4,561 | $134 |
| Valacyclovir | 36 | $2,752 | $76 |
| Dotti | 14 | $1,078 | $77 |
| Progesterone | 17 | $1,067 | $63 |
| Acyclovir | 15 | $482 | $32 |
| Nitrofurantoin Mono-Macro | 12 | $292 | $24 |
| Fluconazole | 16 | $184 | $11 |
2020: 8 drugs
| Estradiol | 88 | $10,049 | $114 |
| Estradiol (Twice Weekly) | 27 | $4,806 | $178 |
| Valacyclovir | 38 | $3,387 | $89 |
| Dotti | 12 | $1,390 | $116 |
| Progesterone | 18 | $1,308 | $73 |
| Acyclovir | 20 | $885 | $44 |
| Medroxyprogesterone Acetate | 18 | $293 | $16 |
| Fluconazole | 25 | $196 | $8 |
2019: 9 drugs
| Estradiol | 120 | $13,927 | $116 |
| Premarin | 11 | $3,639 | $331 |
| Yuvafem | 13 | $3,576 | $275 |
| Valacyclovir | 47 | $2,640 | $56 |
| Progesterone | 33 | $2,125 | $64 |
| Clobetasol Propionate | 17 | $932 | $55 |
| Medroxyprogesterone Acetate | 18 | $244 | $14 |
| Fluconazole | 13 | $214 | $16 |
| Acyclovir | 11 | $139 | $13 |
2018: 7 drugs
| Estradiol | 72 | $7,510 | $104 |
| Yuvafem | 30 | $6,931 | $231 |
| Premarin | 12 | $4,206 | $351 |
| Valacyclovir | 48 | $1,926 | $40 |
| Progesterone | 15 | $1,322 | $88 |
| Medroxyprogesterone Acetate | 15 | $200 | $13 |
| Fluconazole | 15 | $164 | $11 |
2017: 6 drugs
| Vagifem | 20 | $6,529 | $326 |
| Premarin | 17 | $5,788 | $340 |
| Estrace | 15 | $4,835 | $322 |
| Estradiol | 41 | $2,999 | $73 |
| Valacyclovir | 45 | $1,375 | $31 |
| Fluconazole | 17 | $165 | $10 |
2016: 5 drugs
| Vagifem | 23 | $5,476 | $238 |
| Estradiol | 43 | $3,014 | $70 |
| Diflucan | 14 | $2,527 | $180 |
| Valacyclovir | 20 | $754 | $38 |
| Medroxyprogesterone Acetate | 15 | $240 | $16 |
2015: 5 drugs
| Vagifem | 26 | $7,773 | $299 |
| Estradiol | 43 | $1,981 | $46 |
| Diflucan | 15 | $1,882 | $125 |
| Valacyclovir | 14 | $987 | $70 |
| Medroxyprogesterone Acetate | 11 | $188 | $17 |
2014: 6 drugs
| Vagifem | 34 | $5,956 | $175 |
| Vivelle-Dot | 16 | $2,277 | $142 |
| Estrace | 12 | $2,156 | $180 |
| Valacyclovir | 16 | $1,426 | $89 |
| Estradiol | 20 | $333 | $17 |
| Medroxyprogesterone Acetate | 13 | $197 | $15 |
2013: 4 drugs
| Vagifem | 16 | $2,308 | $144 |
| Vivelle-Dot | 13 | $1,108 | $85 |
| Estradiol | 23 | $752 | $33 |
| Fluconazole | 20 | $296 | $15 |
Money from drug and device companies
$32 in 2025
| 2025 | 2 | 2 | None | $32 |
| 2024 | 1 | 1 | None | $3 |
| 2023 | 2 | 3 | None | $46 |
| 2022 | 1 | 1 | None | $27 |
| 2021 | 1 | 1 | None | $12 |
| 2020 | 1 | 1 | None | $14 |
| 2019 | 1 | 1 | None | $16 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biogen | Zurzuvae | $29 | 1 payment
|
| Mayne Pharma Commercial | None | $3 | 1 payment
|
See all 2 published payments
| Mayne Pharma Commercial | Meals · 2025-07-29 | None | $3 |
| Biogen | Meals · 2025-07-09 | Zurzuvae | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3
| Mayne Pharma Commercial | None | $3 | 1 payment
|
2023: $46
| Astellas Pharma US | Veozah | $26 | 1 payment
|
| Mayne Pharma Commercial | None | $20 | 2 payments
|
2022: $27
| Abbvie | Orilissa | $27 | 1 payment
|
2021: $12
| CooperSurgical | Paragard | $12 | 1 payment
|
2020: $14
| Avion Pharmaceuticals | Balcoltra | $14 | 1 payment
|
2019: $16
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
Professional record
- NPI
- 1285731703
- Licence
- CA A64736California A64736: Current · expires 2028-04-30
- Trained
- University of California, Geffen School of Medicine, 1996 · 30 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 5 Bon Air Rd, Suite 117, Larkspur, CA, 94939
- NPI first listed
- 2006-09-19
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.